EuroEyes Delivers Solid Results in 2022
Retrieved on:
Martedì, Marzo 28, 2023
Momentum, Veľké Lovce, San Francisco Chinese New Year Festival and Parade, Travel, Russell Street, Marketing, 2016 EuroEyes Cyclassics, LEC, ICL, HK, COVID-19, LVCP, EBIT, HKD, Republic, EBITDA, Acquisition, Patient, Hong Kong dollar, Chinese New Year, Ophthalmology, United Kingdom, Depreciation, City, Yoy, Relaxation, Retail, Video game, Pharmaceutical industry, PRC, Causeway Bay, Euro
EuroEyes is pleased to announce its annual results for the year ended 31 December 2022 (the "Year").
Key Points:
- EuroEyes is pleased to announce its annual results for the year ended 31 December 2022 (the "Year").
- EuroEyes faced a challenging year in 2022 due to the unfavourable macro environment created by the global COVID-19 pandemic and its related control policies, as well as geopolitical turmoil, inflation and currency fluctuations.
- In 2022, the Group's total revenue was approximately EUR74.0 million, representing an increase of approximately 7.5% YoY (HK$ equivalent: 610.3 million).
- EuroEyes announced the acquisition of the London Vision Clinic ("LoVC") on 20 January 2022 for a completion consideration of GBP13,130,000.